

Jii Bum Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/290970/publications.pdf>

Version: 2024-02-01

17
papers

297
citations

1305906

8
h-index

1181555

14
g-index

19
all docs

19
docs citations

19
times ranked

232
citing authors

#	ARTICLE	IF	CITATIONS
1	Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC. <i>Cancer Discovery</i> , 2022, 12, 16-19.	7.7	7
2	Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). <i>Korean Journal of Internal Medicine</i> , 2022, 37, 190-200.	0.7	2
3	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
4	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	1.2	17
5	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 323-329.	1.3	16
6	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. <i>Scientific Reports</i> , 2021, 11, 8551.	1.6	13
7	Clinical Insights Into Novel Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 681320.	1.6	76
8	Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. <i>Molecules and Cells</i> , 2021, 44, 363-373.	1.0	13
9	Prognostic implications of PD-L1 expression in patients with angiosarcoma. <i>Future Science OA</i> , 2021, 7, FSO691.	0.9	4
10	Abstract CT159: Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC)., 2021,, ,		2
11	Association between <i>Fusobacterium nucleatum</i> and patient prognosis in metastatic colon cancer. <i>Scientific Reports</i> , 2021, 11, 20263.	1.6	11
12	Role and Function of O-GlcNAcylation in Cancer. <i>Cancers</i> , 2021, 13, 5365.	1.7	43
13	Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. <i>Trials</i> , 2020, 21, 320.	0.7	5
14	Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 609313.	1.3	4
15	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. , 2019, 7, 268.		26
16	Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1578-1588.	1.3	5
17	ASO Author Reflections: Prognostic Impact of Body Composition Change After Gastrectomy for Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 765-766.	0.7	0